Table 5.
Associations between the sum of urinary paracetamol metabolites and semen parameters a
| Semen parameter by chemical category b | Unadjusted | Adjusted c |
|---|---|---|
| β (95% CI) | β (95% CI) | |
| General characteristics | ||
| Total count (* 10^6 /ml concentration x volume) | −0.28 (−0.59, 0.02) | −0.18 (−0.51, 0.15) |
| 1st quartile | Ref. | Ref. |
| 2nd quartile | 0.21 (−0.66, 1.07) | 0.52 (−0.40, 1.45) |
| 3rd quartile | 0.32 (−0.55, 1.19) | 0.61 (−0.36, 1.57) |
| 4th quartile | 1.07 (−1.94, −0.21) | −0.67 (−1.63, 0.28) |
| p-for linear trend | 0.02 | 0.16 |
| Motility | ||
| Average path velocity (µm/sec) | −0.67 (−1.61, 0.27) | −0.41 (−1.41, 0.59) |
| 1st quartile | Ref. | Ref. |
| 2nd quartile | 2.59 (−0.08, 5.25) | 2.87 (0.07, 5.68) |
| 3rd quartile | 0.18 (−2.49, 2.86) | 0.26 (−2.66, 3.19) |
| 4th quartile | −1.36 (−4.02, 1.29) | −0.52 (−3.41, 2.37) |
| p-for linear trend | 0.13 | 0.34 |
| Amplitude of lateral head (µm) | −0.10 (−0.21, 0.01) | −0.08 (−0.19, 0.04) |
| 1st quartile | Ref. | Ref. |
| 2nd quartile | −0.06 (−0.37, 0.25) | −0.05 (−0.37, 0.28) |
| 3rd quartile | −0.37 (−0.68, −0.06) | −0.43 (−0.77, −0.09) |
| 4th quartile | −0.21 (−0.52, 0.10) | −0.20 (−0.54, 0.13) |
| p-for linear trend | 0.06 | 0.08 |
| Linearity (% ) | −0.60 (−1.60, 0.39) | −0.21 (−1.27, 0.85) |
| 1st quartile | Ref. | Ref. |
| 2nd quartile | 2.26 (−0.54, 5.06) | 3.13 (0.16, 6.09) |
| 3rd quartile | 1.55 (−1.26, 4.37) | 2.50 (−0.59, 5.59) |
| 4th quartile | −1.55 (−4.34, 1.25) | 0.13 (−2.92, 3.18) |
| p-for linear trend | 0.23 | 0.87 |
| Percent Motility (% ) | −0.21 (−0.42, −0.01) | −0.15 (−0.36, 0.07) |
| 1st quartile | Ref. | Ref. |
| 2nd quartile | 0.07 (−0.51, 0.65) | 0.23 (−0.39, 0.84) |
| 3rd quartile | −0.13 (−0.72, 0.45) | 0.06 (−0.58, 0.70) |
| 4th quartile | −0.46 (−1.04, 0.12) | −0.15 (−0.78, 0.48) |
| p-for linear trend | 0.09 | 0.52 |
| Morphometry | ||
| Other tail abnormalities (%) | −0.01 (−0.06, 0.04) | 0.00 (−0.06, 0.06) |
| 1st quartile | Ref. | Ref. |
| 2nd quartile | −0.20 (−0.36, −0.05) | −0.22 (−0.39, −0.05) |
| 3rd quartile | −0.07 (−0.23, 0.08) | −0.10 (−0.27, 0.07) |
| 4th quartile | −0.07 (−0.23, 0.08) | −0.07 (−0.24, 0.10) |
| p-for linear trend | 0.73 | 0.84 |
| Morphology | ||
| Taper (% ) | −0.01 (−0.07, 0.06) | −0.01 (−0.08, 0.06) |
| 1st quartile | Ref. | Ref. |
| 2nd quartile | −0.17 (−0.35, 0.02) | −0.20 (−0.4, −0.01) |
| 3rd quartile | 0.01 (−0.18, 0.19) | −0.06 (−0.26, 0.15) |
| 4th quartile | −0.03 (−0.22, 0.16) | −0.06 (−0.26, 0.14) |
| p-for linear trend | 0.79 | 0.96 |
Note: Bolded effect estimates and 95% CIs indicate statistical significance.
a
Restricted to parameters with a significant association in unadjusted and/or adjusted models.
b
Effect estimates and 95% CIs are presented for regression models of continuous log-transformed sum of urinary metabolites concentration, unless specified otherwise. Summed urinary paracetamol metabolites quartiles : 1st ( < 606 ng/mL, n=103); 2nd (606 – 1113 ng/mL, n=104); 3rd (1114 – 2029 ng/mL, n=103) and 4th ( ≥ 2083 ng/mL, n=104).
c
Models were adjusted for log-transformed creatinine and age (years).